Friday, July 10, 2026

pharma · Cholestatic liver disease · Cystic Fibrosis · PRQR

ProQR Therapeutics N.V

ProQR Therapeutics is a pharma organization headquartered in Leiden, NL. It trades on NYSE under ticker PRQR. Primary therapeutic focus areas include Cholestatic liver disease, Cystic Fibrosis, Autosomal Dominant Retinit

Leiden, NL HQ
2012 Founded
204 Employees
Public company Type
PRQR · NYSE Ticker
Company details
Status
Public
HQ
Leiden, NL
Founded
2012
Employees
204
Programs
6
Drugs
2
Patents
19
Clinical program

PQ-0810-001

Phase 1 · other · Cholestatic liver disease

PQ-0810-001 for Cholestatic liver disease is a Phase 1 program (other) at ProQR Therapeutics N.V. with 1 ClinicalTrials.gov record(s).

Internal code PQ-0810-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ProQR Therapeutics N.V.
Phase
Phase 1
Modality
other
Indication
Cholestatic liver disease
Status
active
Trials
1

Clinical trials